Blume-Jensen Peter
President and CEO
Blume-Jensen Peter has filed 10 SEC Form 4 filings (15 transaction rows) across 1 company, with disclosures dating back to 2025. 10 of those filings fall inside the rolling window. Most recent filing: Aug 27, 2026.
On the most recent filing, Blume-Jensen Peter is listed as President and CEO at Acrivon Therapeutics, Inc. Inside the rolling window, Blume-Jensen Peter reported 1 open-market purchase totaling $82K in ACRV and 2 open-market sales totaling $34K in ACRV. The largest disclosed transaction in the window is a purchase of 49,000 ACRV shares on Jan 14, 2026, worth $82K.
Companies traded
Other insiders at ACRV
Insider Buying
$82K
reported purchases (SEC code P)
Insider Selling
$34K
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Blume-Jensen Peter made?
Blume-Jensen Peter has filed 10 SEC Form 4 filings (15 transaction rows) across 1 company since 2025.
Which companies does Blume-Jensen Peter trade?
Blume-Jensen Peter has filed SEC Form 4 disclosures for 1 company, including ACRV.
When was Blume-Jensen Peter's most recent SEC Form 4 filing?
Blume-Jensen Peter's most recent SEC Form 4 filing on Tracefour is dated Aug 27, 2026.
What is Blume-Jensen Peter's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Blume-Jensen Peter is listed as President and CEO.
What is Blume-Jensen Peter's total buy and sell value in the current window?
Inside the rolling retention window, Blume-Jensen Peter bought $82K and sold $34K based on SEC Form 4 filings.
What was Blume-Jensen Peter's largest disclosed transaction?
The largest disclosed transaction in the current window is a purchase of 49,000 ACRV shares on 2026-01-14, worth $82K, per SEC Form 4 filings.